Wall Street analyst estimates for HUTCHMED (China) Limited (HCM): consensus price target and buy/hold/sell recommendations.
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally.
Consensus price target
$22.78 (+68 % vs price $13.59)
between $13.60 and $45.00 · 3 targets published in the last quarter
Closing price, Oct 29
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 1 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (−2 sell to +2 buy) | 0.70 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-03-04 | $0.21 | ||
| 2026-07-30 | $0.05 | $0.14 | -68.3% |
| 2026-07-02 | $0.05 | $-0.36 | +112.8% |
| 2026-03-05 | $0.00 | $2.50 | -100.0% |
| 2025-08-07 | $2.60 | $1.46 | +78.1% |
| 2025-07-02 | $1.35 | $-0.32 | +525.9% |
| 2025-03-19 | $0.07 | $0.04 | +75.0% |
| 2025-02-26 | $0.04 | $-0.32 | +111.0% |
Valuation Ratios
| P/E Ratio | 131.94 |
| Price / Book | 1.76 |
| EV / EBITDA | -114.53 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $216.1M | $241.2M | $214.1M | $204.9M | $228.4M | $356.1M | $426.4M | $838.0M | $630.2M | $550.0M |
| Cost of Revenue | $156.3M | $175.8M | $143.9M | $160.2M | $188.8M | $28.8M | $311.1M | $384.4M | $347.6M | $337.2M |
| Gross Profit | $59.8M | $65.4M | $70.2M | $44.7M | $39.5M | $327.3M | $115.3M | $453.6M | $282.6M | $212.7M |
| Research & Development | $66.9M | $75.8M | $115.6M | $91.9M | $176.7M | $299.1M | $386.9M | $303.1M | $213.4M | $164.1M |
| Selling, General & Admin | $39.6M | $43.3M | $48.6M | $52.9M | $61.5M | $127.1M | $136.1M | $133.2M | $112.9M | $103.3M |
| Operating Expenses | $106.6M | $118.8M | $162.8M | $197.3M | $238.1M | $684.4M | $834.1M | $436.2M | $326.3M | $267.4M |
| Operating Income | -$46.7M | -$53.4M | -$92.6M | -$152.8M | -$198.6M | -$357.1M | -$718.8M | $18.4M | -$43.7M | -$54.7M |
| EBITDA | -$43.4M | -$49.5M | -$82.1M | -$135.1M | -$192.6M | -$147.3M | -$351.4M | $26.6M | -$31.4M | -$41.4M |
| Interest Expense | $1.6M | $1.5M | $1.0M | $1.0M | $788,354 | $592,000 | $652,000 | $759,000 | $2.9M | $2.9M |
| Pre-tax Income | $18.9M | -$19.9M | -$67.3M | -$100.6M | -$110.9M | -$155.1M | -$360.7M | $105.6M | $45.4M | $522.7M |
| Income Tax | $4.3M | $3.1M | $4.0M | $3.3M | $4.8M | $11.9M | -$283,000 | $4.5M | $7.2M | $63.8M |
| Net Income | $11.7M | -$26.7M | -$74.8M | -$106.0M | -$125.9M | -$194.6M | -$360.8M | $100.8M | $37.7M | $458.1M |
| EPS | $0.10 | $-0.22 | $-0.55 | $-0.80 | $-4.50 | $-1.25 | $-2.15 | $0.60 | $0.22 | $2.65 |
| EPS (Diluted) | $0.10 | $-0.22 | $-0.55 | $-0.80 | $-4.50 | $-1.25 | $-2.15 | $0.60 | $0.22 | $2.60 |
| Shares Outstanding (Diluted) | 119.9 M | 123.4 M | 132.9 M | 133.1 M | 27.9 M | 158.5 M | 169.4 M | 173.8 M | 174.6 M | 174.6 M |
Price
| Price | $13.59 (closing price, October 29, 2026) |
| Market Cap | $2.4B |
| Exchange | NASDAQ |
| Country | HK |
Related companies: BNTX · INCY · GMAB · EXEL · LEGN · IDYA · ZLAB · RCUS
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of HCM: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks